Clinical Trial

A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC

Name: A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC — clinical trial record (NCT07510594)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To explore the Objective Response Rate (ORR) of Benmelstobart combined with Anlotinib and chemotherapy as first-line treatment for large-cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinoma (EP-NEC)

Trial Details

NCT Number	NCT07510594
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma
Enrollment	48 participants
Start Date	2026-05-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-03